CEOInterviews.AI
Start App
Try: AI strategy tariffs earnings guidance layoffs interest rates growth

Louise Rodino-Klapac

Executive Vice President, Chief Scientific Officer and Head of Research & Development, Sarepta Therapeutics, Inc.

Search every verified Louise Rodino-Klapac interview, podcast appearance, and on-the-record quote — each transcript cross-checked by AI and human review to confirm speaker identity. Louise Rodino-Klapac, Executive Vice President, Chief Scientific Officer and Head of Research & Development at Iteos Therapeutics, appeared on the podcast "DNA Today" on September 17, 2023, to discuss limb-girdle muscular dystrophies (LGMD). During the episode, she stated that the subtypes her team at Sarepta is researching cover about 70 percent of the LGMD population, and described their goal as delivering a newly functioning version of the relevant gene to make the missing protein. She explained that gene therapy involves adding a normal functioning copy of a gene rather than altering the genome, and that each LGMD subtype requires a tailored therapy because each is caused by a mutation in a different gene. Rodino-Klapac noted that clinical trials for various LGMD subtypes are mostly in phase one, evaluating safety and early efficacy, with hopes for approval within the next decade. She emphasized that the goal of gene therapy is to stabilize or slow disease progression, and that earlier intervention may lead to better outcomes. She encouraged patients to join registries for their specific subtype, stating that natural history studies are critical for understanding the disease and necessary for clinical trials. She also discussed the availability of industry-supported genetic testing programs at commercial laboratories that offer testing at no cost or reduced cost to patients.

Recent appearances

  • Sarepta Therapeutics Q2 2026 Earnings Call | ELEVIDYS Commercial Gene Therapy Sales Up

    August 10, 2026 · 📺 i101

    Sarepta Therapeutics Q2 2026 Earnings Conference Call. Twitter - https://x.com/i101yt If you find our work useful, please support us by purchasing a Super Thanks— it truly helps us a lot. #earningscall #StockMarketNews #conferenceCall Earnings Call | Earnings Conference Call | Earnings concall | concall | quarterly results | Stock News | Full Year results | Fiscal Year results | investment news | stock latest news | Annual Meeting of Shareholders | Annual Meeting of Unitholders | Special and Annual Meeting of Shareholders | AGM | Annual General Meeting If you want us to remove your compa…

    Watch on YouTube ↗

  • Industry Deep Dive With Sarepta Therapeutics

    July 10, 2026 · 📺 LGMD Channel hosted by The Speak Foundation

    Join hosts Kat and Pat as they sit down with Dr. Louise Rodino-Klapac (Head of R&D) and Dr. James Richardson (CMO) from Sarepta. This episode shines a light on the clinical hold that the FDA has put on the company’s research into LGMD 2e. We discuss the past and the path forward as industry works to balance communication of difficult news along with trying to help families understand why the clinical trial landscape is not a straight and easy path.

    Watch on YouTube ↗

  • $SRPT Sarepta Therapeutics Q3 2025 Earnings Conference Call

    November 03, 2025 · 📺 EARNMOAR

    11/03/2025 Q&A: 35:05 Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat Duchenne muscular dystrophy (Duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of Duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatme…

    Watch on YouTube ↗

  • Sarepta Therapeutics - Analyst Q&A Regarding LGMD Programs | July 18, 2025

    July 18, 2025 · 📺 i101

    Sarepta Therapeutics Analyst Q&A Regarding LGMD Programs with senior management. Q2 2025 Earnings Conference Call. #earningscall #StockMarketNews

    Watch on YouTube ↗

  • Limb-Girdle Muscular Dystrophies with Louise Rodino-Klapac and Livija Medne

    March 10, 2023 · 📺 DNA Today

    In this episode, we are exploring limb-girdle muscular dystrophy (LGMD). Joining us for this conversation are two experts, Dr.

    Watch on YouTube ↗

The summary and quote tags on this profile are produced with AI assistance from verified, first-person interview transcripts, then checked by our team to confirm the speaker's identity and the accuracy of every quote. See how we verify →